Sample size reestimation for clinical trials with censored survival data

Journal of the American Statistical Association

Volumn 98, Issue 462, 2003, Pages 418-426

  Shen, Yu ^a   Cai, Jianwen ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b IL   (United States)

Author keywords

Clinical trial; Group sequential procedure; Self design; Survival data with staggered entry; Weighted linear rank statistic

Indexed keywords

EID: 0042243486     PISSN: 01621459     EISSN: None     Source Type: Journal    
DOI: 10.1198/016214503000206     Document Type: Article

References (30)

1. Andersen, P. K. (1987), "Conditional Power Calculations as an Aid in the Decision Whether to Continue a Clinical Trial," Controlled Clinical Trials, 8, 67-74.
2. Bauer, P., and Kohne, K. (1994), "Evaluations of Experiments With Adaptive Interim Analyses," Biometrics, 50, 1029-1041.
3. Colton, T., and McPherson, K. (1976), "Two-Stage Plans Compared With Fixed-Sample-Size and Wald SPRT Plans," Journal of the American Statistical Association, 71, 80-86.
4. Cui, L., Hung, H. M., and Wang, S. J. (1999), "Modification of Sample Size in Group Sequential Clinical Trials," Biometrics, 55, 853-857.
5. DeMets, D. L., and Ware, J. H. (1980), "Group Sequential Methods for Clinical Trials With a One-Sided Hypothesis," Biometrika, 67, 651-660.
6. Fisher, L. (1998), "Self-Designing Clinical Trials," Statistics in Medicine, 17, 1551-1562.
7. Fleming, T. R., and Harrington, D. P. (1991), Counting Processes Survival Analysis, New York: Wiley.
8. Gail, M. H., DeMets, D. L., and Slud, E. V. (1982), "Simulation Studies on Increments of the Two-Sample Logrank Score Test for Survival Time Data, with Application to Group Sequential Boundaries," in Survival Analysis, eds. J. Crowley and R. A. Johnson, Hayward, CA: Institute of Mathematical Statistics, pp. 287-301.
9. Gould, A. L. (1992), "Interim Analyses for Monitoring Clinical Trials That do not Materially Affect the Type I Error Rate," Statistics in Medicine, 11, 5566.
10. Kim, K., and Tsiatis, A. A. (1990), "Study Duration for Clinical Trials With Survival Response and Early Stopping Rule," Biometrics, 46, 81-92.
11. Lachin, J. M. (1981), "Introduction to Sample Size Determination and Power Analysis for Clinical Trials," Controlled Clinical Trials, 2, 93-113.
12. Lan, K. K. G., and Lachin, J. M. (1990), "Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial," Biometrics, 46, 759-770.
13. Laurie, J. A., Moertel, C. G., Fleming, T. R., Wieand, H. S., Leigh, J. E., Rubin, J., McComack, G. W., Gerstner, J. B., Krook, J. E., Malliard, J., Twito, D. I., Morton, R. F., Tschetter, L. K., Barlow, J. F. (1989), "Surgical Adjuvant Therapy of Large-Bowel Carcinoma: An Evaluation of Levamisole and the Combination of Levamisole and Fluorouracil," Journal of Clinical Oncology, 7, 1447-1456.
14. Lin, D. Y. (1991), "Nonparametric Sequential Testing in Clinical Trials With Incomplete Multivariate Observations," Biometrika, 78, 123-131.
15. Lin, D. Y., Yao, Q., and Ying, Z. (1999), "A General Theory on Stochastic Curtailment for Censored Survival Data," Journal of the American Statistical Association, 94, 510-521.
16. Liu, Q., and Chi, G. Y. H. (2001), "On Sample Size and Inference for Two-Stage Adaptive Designs," Biometrics, 57, 172-177.
17. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Click, J. H., and et al (1990), "Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma," The New England Journal of Medicine, 322, 352-358.
18. Oakes, D. (2001), "Biometrika Centenary: Survival Analysis," Biometrika, 88, 99-142.
19. O'Brien, P. C., and Fleming, T. R. (1979), "A Multiple Testing Procedure for Clinical Trials," Biometrics, 5, 549-556.
20. Pocock, S. J. (1977), "Group Sequential Methods in the Design and Analysis of Clinical Trials," Biometrika, 64, 191-199.
21. Proschan, M. A., and Hunsberger, S. A. (1995), "Designed Extension of Studies Based on Conditional Power," Biometrics, 51, 1315-1324.
22. Rubinstein, L. V., Gail, M. H., and Santner, T. J. (1981), "Planning the Duration of a Comparative Clinical Trial With Loss to Follow-Up and a Period of Continued Observation," Journal of Chronical Diseases, 34, 469-479.
23. Schoenfeld, D. A. (1983), "Sample-Size Formula for the Proportional-Hazards Regression Model," Biometrics, 39, 499-503.
24. Shen, Y., and Fisher, L. (1999), "Statistical Inference for Self-Designing Clinical Trials With a One-Sided Hypothesis," Biometrics, 55, 190-197.
25. Shih, W. J. (1992), "Sample Size Reestimation in Clinical Trials," in Biopharmaceutical Sequential Statistical Applications, ed. K. E. Peace, New York: Marcel Dekker, pp. 285-301.
26. Slud, E. V., and Wei, L. J. (1982), "Two-Sample Repeated Significance Tests Based on the Modified Wilcoxon Statistic," Journal of the American Statistical Association, 77, 862-868.
27. Tsiatis, A. A. (1981), "The Asymptotic Joint Distribution of the Efficient Scores Test for the Proportional Hazards Model Calculated Over Time," Biometrika, 68, 311-315.
28. _ (1982), "Repeated Significance Testing for a General Class of Statistics Used in Censored Survival Data," Journal of American Statistical Association, 77, 855-861.
29. Tsiatis, A. A., Rosner, G. L., and Tritchler, D. L. (1985), "Group Sequential Tests With Censored Survival Data Adjusting for Covariates," Biometrika, 72, 365-373.
30. Wassmer, G. (1998), "A Comparison of Two Methods for Adaptive Interim Analyses in Clinical Trials," Biometrics, 54, 696-705.